enGene Therapeutics Inc. (ENGN)

enGene Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is November - October.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Apr 30, 2026	Oct 31, 2025	Oct 31, 2024	Oct 31, 2023	Dec 31, 2022	Oct 31, 2022
Cash & Equivalents	29.83	50.15	173	81.52	20.43	20.43
Short-Term Investments	228.71	143.66	65.4	0.08	0.07	0.07
Cash & Short-Term Investments	258.54	193.82	238.4	81.6	20.51	20.51
Cash Growth	18.89%	-18.70%	192.17%	297.88%	0%	-
Other Receivables	0.82	0.93	0.33	2.34	1.34	1.34
Total Trade Receivables	0.82	0.93	0.33	2.34	1.34	1.34
Other Current Assets	10.64	6.65	8.63	1.5	0.74	0.74
Total Current Assets	270	201.39	247.36	85.44	22.58	22.58
Net Property, Plant & Equipment	9.44	10.19	2.91	0.59	0.39	0.39
Long-Term Investments	26.71	8.52	59.53	-	-	-
Other Long-Term Assets	1.38	1.36	1.37	0.93	0.94	0.94
Total Assets	307.52	221.47	311.17	86.96	23.91	23.91

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Apr 30, 2026	Oct 31, 2025	Oct 31, 2024	Oct 31, 2023	Dec 31, 2022	Oct 31, 2022
Accounts Payable	1.79	6.69	1.41	1.16	0.72	0.72
Accrued Expenses	17.21	15.28	12.13	3.54	3.12	3.12
Current Portion of Long-Term Debt	0.19	8	0.7	0.56	1.27	1.27
Current Portion of Leases	2.29	2.01	0.42	-	-	-
Total Current Liabilities	21.49	31.98	14.66	5.26	5.1	5.1
Long-Term Debt	24.91	15.32	22.47	9.22	27.05	27.05
Long-Term Leases	5.96	6.46	1.43	-	-	-
Other Long-Term Liabilities	-	-	-	-	15.25	15.25
Total Long-Term Liabilities	30.87	21.78	23.9	9.22	42.3	42.3
Total Liabilities	52.36	53.76	38.56	14.47	47.41	47.41

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Apr 30, 2026	Oct 31, 2025	Oct 31, 2024	Oct 31, 2023	Dec 31, 2022	Oct 31, 2022
Common Stock	632	513.28	509.81	259.37	16.39	16.39
Additional Paid-in Capital	56.33	27.35	18.95	13.72	7.68	7.68
Accumulated Other Comprehensive Income	-1.14	-0.89	-1.42	-1.02	-1.02	-1.02
Retained Earnings	-432.01	-372.03	-254.73	-199.59	-99.67	-99.67
Total Common Shareholders' Equity	255.17	167.71	272.61	72.49	-76.61	-76.61
Minority Interest	-	-	-	-	53.12	53.12
Shareholders' Equity	255.17	167.71	272.61	72.49	-23.5	-23.5
Total Liabilities & Equity	307.52	221.47	311.17	86.96	23.91	23.91

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Apr 30, 2026	Oct 31, 2025	Oct 31, 2024	Oct 31, 2023	Dec 31, 2022	Oct 31, 2022
Total Debt	33.35	31.8	25.02	9.78	28.32	28.32
Net Cash (Debt)	225.19	162.02	213.38	71.82	-7.81	-7.81
Net Cash Growth	17.22%	-24.07%	197.11%	-	-	-
Net Cash Per Share	3.76	3.17	5.65	103.69	-11.73	-11.92
Book Value	255.17	167.71	272.61	72.49	-76.61	-76.61
Book Value Per Share	4.26	3.28	7.22	104.66	-115.08	-116.94
Tangible Book Value	255.17	167.71	272.61	72.49	-76.61	-76.61
Tangible Book Value Per Share	4.26	3.28	7.22	104.66	-115.08	-116.94

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: Jun 15, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 27, 2026

Data Sources Report a data error